Retrospective Study
Copyright ©The Author(s) 2025.
World J Gastrointest Endosc. Jun 16, 2025; 17(6): 104234
Published online Jun 16, 2025. doi: 10.4253/wjge.v17.i6.104234
Table 1 Baseline demographics of the patients
Before endoscopy (pre-treatment)
Intravenous injection of PPI (n = 61)
Per oral intake, PCAB (n = 44)
P value
Age (year), mean ± SD68.83 ± 15.9671.21 ± 15.590.47
Male sex, n (%)46 (75.4)26 (59.1)0.20
Current smoker25100.08
Alcohol19100.47
Causes of bleeding
Gastric ulcer26240.71
Duodenal ulcer2414-
Both116-
Helicobacter pylori32150.12
Anti-platelet agents16120.25
Anti-coagulant (NOAC)350.17
NSAIDs/COX 2 inhibitors12110.38
ASA status--0.12
165-
24425-
3914-
420-
Glasgow-Blatchford score, mean ± SD10.27 ± 4.639.97 ± 4.150.75
Rockall score, mean ± SD5.85 ± 2.185.30 ± 1.650.18
AIMS65 score, mean ± SD1.38 ± 1.111.12 ± 0.570.17
Therapeutic intervention3310< 0.01
Forrest classification
I and IIa275< 0.01
Re-bleeding episode1320.02
In-hospital61-
Out-patient71-
Table 2 Multivariate analysis related to therapeutic intervention
Variables
OR
95%CI
P value
Age (year), mean ± SD1.0050.972-1.0390.777
Male sex0.5480.184-1.6320.280
Helicobacter pylori infection1.3310.528-3.3560.544
Use of anti-coagulants0.9940.193-5.1200.994
Use of anti-platelet1.2990.493-3.4230.596
PCAB (vs PPI)0.2720.111-0.6650.004a
Table 3 Multivariate analysis related to rebleeding
Variables
OR
95%CI
P value
Age (year), mean ± SD1.0010.950-1.0540.977
Male sex0.8040.153-4.2160.797
Helicobacter pylori infection0.6240.151-2.5840.515
Use of anti-coagulants9.2061.144-74.1110.037a
Use of anti-platelet2.2430.618-8.1310.219
Forrest classification (≥ IIa)1.8220.499-6.6550.364
PCAB (vs PPI)0.1410.024-0.8440.032a